



For Immediate Release
January 5, 2005

Contact: Bob Linton
Dudnyk Public Relations
+1.267.532.1298
blinton@dudnyk.com

Fujirebio Diagnostics, Inc. Appoints Dr. W. Jeffrey Allard Vice President and Chief Scientific Officer

MALVERN, Pa. — Fujirebio Diagnostics, Inc. (FDI), a world leader in in-vitro diagnostics, has appointed Dr. W. Jeffrey Allard as vice president and chief scientific officer for the company. Dr. Allard is a biochemist and immunologist with more than 25 years of experience and holds eight patents for key diagnostic processes.

At FDI, Dr. Allard will assist in the selection process for new product candidates and their introduction into global markets. In addition, he will manage FDI's expanding global network of in-licensing institutions and promote the company's continuing relationships with research organizations. Dr. Allard will direct FDI's research and development, clinical/regulatory affairs and process engineering staff.

FDI president and COO Paul Touhey commented, "Jeff will be an important part of the FDI management team, helping drive the strategic direction for existing and new diagnostic products in our development pipeline. His expertise in designing research programs, overseeing clinical trials and managing regulatory affairs will be invaluable as FDI seeks to launch new biomarkers with the potential to detect and monitor specific cancers in their early stages."

Dr. Allard comes to FDI from Immunicon Corporation, where he was vice president of clinical research and development. Earlier, he was director of clinical and regulatory oncology for Bayer Corporation and was a diagnostics researcher for E.I. du Pont de Nemours.

-more-

Dr. Allard holds a Ph.D. in biochemistry from Dartmouth College, an M.S. in immunology from Idaho State University and a B.S. (cum laude) in pre-veterinary medicine from the University of New Hampshire. He has authored nearly 100 scientific papers and abstracts and received numerous scientific awards, including two Bayer R&D achievement awards for the U.S. introduction of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA).

He resides in North Wales, Pa., with his wife, Elizabeth Baird, and their two children.

About FDI

Fujirebio Diagnostics, Inc. (FDI) is a premier diagnostics company and the industry leader in tumor marker assays. FDI specializes in the clinical development, manufacturing and commercialization of in vitro diagnostic products for the management of human disease states, with an emphasis in oncology. In November 1998, Fujirebio, Inc. of Tokyo, Japan, acquired the company, formerly known as Centocor Diagnostics. FDI utilizes its worldwide distribution network to enable access by physicians and patients to its diagnostic products. For more information about FDI, please call 610-240-3800 or visit www.fdi.com.

#

